Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Jesus G. Berdeja, MD
Director of Myeloma Research; Principal Investigator
Dr. Berdeja joined Sarah Cannon in 2008 and serves as the director of myeloma research. His responsibilities include seeing patients with all types of blood cancers and patients undergoing blood or marrow transplantation. He is the lead investigator in many clinical trials for patients with blood cancers and has published extensively in the subject.
Berdeja received his undergraduate degree from Stanford University in 1990 and medical degree from Harvard Medical School in 1994. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco. He also completed fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. He is board certified in internal medicine, medical oncology and hematology. Additionally, he is an associate with Tennessee Oncology, PLLC.